Abstract 393P
Background
Pulmonary mucinous epidermoid carcinoma (PMEC) is malignant and extremely rare. With only few case reports or small case series are reported, the prognosis of PMEC is not fully understood. In this study, we aimed to evaluate the prognostic factors of PMEC and to establish a prognostic nomogram model to predict its cancer-specific survival (CSS).
Methods
Within the Surveillance, Epidemiology, and End Results (SEER) Database from its inception to December 31, 2016, patients diagnosed with PMEC were retrospectively identified. Kaplan–Meier analysis and Cox regression were performed to evaluate the CSS stratified by different covariates. A predictive model of nomograms was conducted and the Concordance index (C-index) and calibration curves were used to validate the model.
Results
A total of 585 PMEC patients are identified. The 5-, 10-, and 20-year CSS of stage I-II PMEC were 96.0%, 91.4%, and 88.9%, respectively. The 1-, 3-, 5-, and 10-year CSS of stage III-IV PMEC were 56.5%, 39.45%, 32.1%, 29.4%, respectively. The results of survival curves showed that patients with older ages, larger tumor sizes, bilateral tumors, poorer differentiation and higher stage of T, N and M aligned with poorer prognosis. Surgical treatment significantly improved the patients’ CSS (P < 0.001). But combined therapy didn't present better CSS results than surgery alone did. The multivariate COX results revealed that the covariates of age, bilateral tumor, tumor sizes, pathological differentiation grade, T stage, N stage, M stage and therapy were independent prognosis factors for PMEC. These factors were used to construct a nomogram. The C-index of the nomogram was 0.921. The calibration curve showed that favorable consistency between the predicted PMEC CSS and the actual observation. Validation of the nomogram was conducted with the validation cohort. The C-index of validation was 0.968, and the calibration curve showed favorable consistency.
Conclusions
Age, bilateral tumor, tumor sizes, pathological differentiation grade, T stage, N stage, M stage, and therapy were independent prognosis factors of PMEC patients. A nomogram on predicting the CSS of PMEC was first built and validated, showing its potential value in practice.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
Lingxiao Qiu.
Funding
The National Natural Science Foundation of China (No.81874042).
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
183P - Textbook outcome as a measure of surgical quality assessment and prognosis in gastric neuroendocrine carcinoma: A large multicenter sample analysis
Presenter: You-Xin Gao
Session: e-Poster Display Session
184P - Development and external validation of a nomogram to predict recurrence-free survival after R0 resection for stage II/III gastric adenocarcinoma: An international multicenter study
Presenter: Bin-Bin Xu
Session: e-Poster Display Session
185P - Effect of sarcopenia on short- and long-term outcomes of patients with gastric neuroendocrine tumour after radical surgery: Results from a large, two-institutional series
Presenter: Ling-Qian Wang
Session: e-Poster Display Session
186P - Characterization of the gastroenteropancreatic neuroendocrine tumour patient journey
Presenter: George Fisher Jr
Session: e-Poster Display Session
187P - More is not always better: A multicenter study in lymphadenectomy during gastrectomy for gastric neuroendocrine carcinoma
Presenter: Qi-Yue Chen
Session: e-Poster Display Session
188P - The impact of sarcopenia on chemotherapy toxicity and survival rate among pancreatic cancer patients who underwent chemotherapy: A systematic review and meta-analysis
Presenter: Billy Susanto
Session: e-Poster Display Session
189P - Prognostic value of inflammation-based score for patients treated with FOLFIRINOX (FFX) or gemcitabine plus nab-paclitaxel (GnP)
Presenter: Takahiro Yamamura
Session: e-Poster Display Session
190P - Outcomes from the Asian region of the phase III APACT trial of adjuvant nab-paclitaxel plus gemcitabine (nab-P/G) vs gemcitabine (G) alone for patients (pts) with resected pancreatic cancer (PC)
Presenter: Joon Oh Park
Session: e-Poster Display Session
191P - First-line liposomal irinotecan + 5 fluorouracil/leucovorin + oxaliplatin in patients with pancreatic ductal adenocarcinoma: Results from a phase I/II study
Presenter: Andrew Dean
Session: e-Poster Display Session
192P - A multicenter crossover analysis of first and second-line FOLFIRINOX or gemcitabine plus nab-paclitaxel administered to pancreatic cancer patients: Results from the NAPOLEON study
Presenter: Kenta Nio
Session: e-Poster Display Session